AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29317604 — intervention group
Group type: EXPERIMENTAL
Intervention: AHR involvement
Number of subjects: 290
Study 29318039 — intervention group
Group type: EXPERIMENTAL
Intervention: 27-gauge pars plana vitrectomy (PPV)
Number of subjects: 47
Study 29318647 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea treatment
Number of subjects: 635
Study 29318759 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary sodium intake of 500 mg/d higher
Number of subjects: 16156
Study 29318759 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher sodium intake
Number of subjects: 16156
Study 29318759 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher potassium intake
Number of subjects: 16156
Study 29318795 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 1.0 MAC (T1)
Number of subjects: 20
Study 29318795 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 1.5 MAC (T2)
Number of subjects: 20
Study 29318795 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 2.0 MAC (T3)
Number of subjects: 20
Study 29318795 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane increments (1.0-2.0 MAC)
Number of subjects: 20
Study 29318795 — intervention group
Group type: COMPARATOR
Intervention: Comparison of S' values between T1, T2, and T3
Number of subjects: 20
Study 29318795 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion rates at T1, T2, and T3
Number of subjects: 20
Study 29319721 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin infusion at 0.04 U/min for one hour
Number of subjects: 18
Study 29319721 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin infusion
Number of subjects: 18
Study 29319721 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline noradrenaline dose
Number of subjects: 18
Study 29319721 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline dose higher than 0.38 mcg/kg/min
Number of subjects: 18
Study 29319932 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate 200 mg (single oral dose)
Number of subjects: 28
Study 29319932 — intervention group
Group type: COMPARATOR
Intervention: Younger control (18-45 years)
Number of subjects: 28
Study 29320312 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab for HER2-amplified/overexpressing colorectal cancer
Number of subjects: 251
Study 29320312 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib for EGFR-altered tumors
Number of subjects: 251
Study 29320312 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib for BRAF V600-mutated tumors
Number of subjects: 251
Study 29320312 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib for Hedgehog pathway-altered tumors
Number of subjects: 251
Study 29320346 — intervention group
Group type: COMPARATOR
Intervention: Children with no bedroom media devices
Number of subjects: 90
Study 29320346 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with bedroom media devices
Number of subjects: 90
Study 29320994 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based continuing education program in blood pressure measurement (30-min online educational program)
Number of subjects: 88
Study 29320994 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based continuing education program in blood pressure measurement
Number of subjects: 88
Study 29321007 — intervention group
Group type: EXPERIMENTAL
Intervention: Staging laparoscopy (SL)
Number of subjects: 450
Study 29321022 — intervention group
Group type: COMPARATOR
Intervention: Serum metabolic profiling using ultra high-performance liquid chromatography coupled to high-resolution mass spectrometry (UHPLC-HRMS) in IPF patients.
Number of subjects: 21
Study 29321022 — intervention group
Group type: COMPARATOR
Intervention: LysoPC identified as a potential biomarker in serum of patients with IPF.
Number of subjects: 21
Study 29321026 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination intervention administered by trained lay health workers including appointment reminders via text and phone calls, follow-up and tracking for missed clinic visits, PMTCT health education at home visits and during clinic visits, and retention and adherence support and counseling.
Number of subjects: 0
Study 29321026 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination intervention administered by trained lay health workers.
Number of subjects: 0
Study 29321034 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance imaging (CMR)
Number of subjects: 154
Study 29321034 — intervention group
Group type: EXPERIMENTAL
Intervention: New CMR diagnosis
Number of subjects: 154
Study 29321041 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic proton pump inhibitor
Number of subjects: 3350
Study 29321063 — intervention group
Group type: EXPERIMENTAL
Intervention: Local treatment with autologous adipose-derived stromal vascular fraction (ADSVF) and microfat; 14 ml of microfat and approximately 20 million viable ADSVF cells injected.
Number of subjects: 1
Study 29321075 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 vaccine alone (group 1)
Number of subjects: 39
Study 29321075 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 formulated with the adjuvant IC31® (groups 2, 3, and 4)
Number of subjects: 39
Study 29321075 — intervention group
Group type: EXPERIMENTAL
Intervention: H1/IC31® vaccine (groups 2, 3, and 4)
Number of subjects: 39
Study 29321126 — intervention group
Group type: EXPERIMENTAL
Intervention: SIAM text messages sent at 48 hours after discharge, then at day 8 and day 15, and months 1, 2, 3, 4, 5, and 6.
Number of subjects: 244
Study 29321126 — intervention group
Group type: EXPERIMENTAL
Intervention: SIAM text messages
Number of subjects: 244
Study 29321155 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasminogen replacement therapy
Number of subjects: 0
Study 29322062 — intervention group
Group type: EXPERIMENTAL
Intervention: High KT ratio
Number of subjects: 96
Study 29322062 — intervention group
Group type: COMPARATOR
Intervention: Control group (survived without progression)
Number of subjects: 96
Study 29322091 — intervention group
Group type: EXPERIMENTAL
Intervention: Toca 511 (gamma retroviral replicating vector encoding cytosine deaminase) followed by 5-fluorocytosine (5-FC)
Number of subjects: 0
Study 29322091 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorocytosine (5-FC)
Number of subjects: 0
Study 29322091 — intervention group
Group type: COMPARATOR
Intervention: Toca 511 and Toca FC (extended-release 5-FC)
Number of subjects: 0
Study 29322849 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 239
Study 29322849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 29324537 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 160
Study 29324537 — intervention group
Group type: COMPARATOR
Intervention: Primary debulking surgery (PDS)
Number of subjects: 160
Study 29324603 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy-associated hypertension (gestational hypertension and preeclampsia)
Number of subjects: 979
Study 29324603 — intervention group
Group type: COMPARATOR
Intervention: Normotensive pregnancies (reference group)
Number of subjects: 979
Study 29324745 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital intervention for ADHD, 28 days of at-home treatment
Number of subjects: 80
Study 29324985 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine Tuberculosis Lipoarabinomannan
Number of subjects: 0
Study 29324996 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory-confirmed viral respiratory infections (influenza, parainfluenza, rhinovirus, respiratory syncytial virus [RSV], adenovirus, human metapneumovirus [HMPV])
Number of subjects: 1347
Study 29324996 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenovirus, rhinovirus, and RSV
Number of subjects: 1347
Study 29324996 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory infections
Number of subjects: 1347
Study 29324996 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of respiratory infection (HMPV, RSV, influenza, rhinovirus, adenovirus)
Number of subjects: 1347
Study 29325058 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of trimethyllysine (TML)
Number of subjects: 2519
Study 29325058 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of palmitoylcarnitine
Number of subjects: 2519
Study 29325058 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of γ-butyrobetaine
Number of subjects: 2519
Study 29325121 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D (25OHD) concentrations in plasma
Number of subjects: 4114
Study 29325133 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (daily for 24 months)
Number of subjects: 119
Study 29325161 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) booster
Number of subjects: 0
Study 29325173 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine (PCV13) or pneumococcal polysaccharide vaccine (PPV23)
Number of subjects: 44
Study 29325173 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine (PPV23)
Number of subjects: 44
Study 29325173 — intervention group
Group type: COMPARATOR
Intervention: N/A (Control group)
Number of subjects: 44
Study 29325173 — intervention group
Group type: EXPERIMENTAL
Intervention: N/A (All groups)
Number of subjects: 44
Study 29325173 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 or PPV23
Number of subjects: 44
Study 29325238 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Number of subjects: 124
Study 29325238 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention
Number of subjects: 124
Study 29325238 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 124
Study 29325238 — intervention group
Group type: COMPARATOR
Intervention: Control group (not prescribed antidepressants)
Number of subjects: 124
Study 29325434 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 323
Study 29325521 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent gemcitabine (1000 mg/m²)
Number of subjects: 30
Study 29325521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus gemcitabine
Number of subjects: 30
Study 29325546 — intervention group
Group type: EXPERIMENTAL
Intervention: Irritation scale (9 items, alpha=0.88)
Number of subjects: 907
Study 29325546 — intervention group
Group type: EXPERIMENTAL
Intervention: Debris scale (4 items, alpha=0.85)
Number of subjects: 907
Study 29325546 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reports of puffy eyes
Number of subjects: 907
Study 29325546 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reports of red eyes
Number of subjects: 907
Study 29325546 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reports of debris
Number of subjects: 907
Study 29325546 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reports of irritation
Number of subjects: 907
Study 29325548 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cancer screening decision aid video
Number of subjects: 50
Study 29325578 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led brisk walking programme (10-15 mins throughout the school week)
Number of subjects: 199
Study 29325578 — intervention group
Group type: COMPARATOR
Intervention: Usual physical activity (control group)
Number of subjects: 199
Study 29325583 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative care approach (IntCare)
Number of subjects: 112
Study 29325583 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UsCare)
Number of subjects: 112
Study 29325586 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency percussive ventilation (HFPV)
Number of subjects: 8
Study 29325595 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus of 10% dextrose 5 mL/kg followed by a dextrose infusion in addition to standard care
Number of subjects: 1266
Study 29325595 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 1266
Study 29325707 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle biopsy (EUS-FNB) sampling using a 22-gauge needle
Number of subjects: 37
Study 29326029 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (8 mg/kg loading dose followed by 6 mg/kg), Pertuzumab (840 mg loading dose followed by 420 mg), Palbociclib (125 mg once a day for 21 days), Fulvestrant (500 mg every 4 weeks)
Number of subjects: 30
Study 29326031 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroop Task performance
Number of subjects: 46
Study 29326031 — intervention group
Group type: EXPERIMENTAL
Intervention: Wisconsin Card Sorting Task (WCST) performance
Number of subjects: 46
Study 29326031 — intervention group
Group type: EXPERIMENTAL
Intervention: Iowa Gambling Task (IGT) performance
Number of subjects: 46
Study 29326031 — intervention group
Group type: EXPERIMENTAL
Intervention: Inventory for Depressive Symptomatology (IDS-SR) scores
Number of subjects: 46
Study 29326031 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate linear model including Stroop interference and IDS-SR
Number of subjects: 46
Study 29326093 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional face-to-face weight loss program
Number of subjects: 81
Study 29326093 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss app program
Number of subjects: 81
Study 29326093 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial face-to-face and partial app program (combi group)
Number of subjects: 81
Study 29326093 — intervention group
Group type: COMPARATOR
Intervention: Control group (no information provided)
Number of subjects: 81
Study 29326093 — intervention group
Group type: EXPERIMENTAL
Intervention: Combi group
Number of subjects: 81
Study 29326093 — intervention group
Group type: EXPERIMENTAL
Intervention: App group
Number of subjects: 81
Study 29326107 — intervention group
Group type: EXPERIMENTAL
Intervention: rs7903146 T allele homozygotes
Number of subjects: 608
Study 29326107 — intervention group
Group type: EXPERIMENTAL
Intervention: T allele
Number of subjects: 608
Study 29326293 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN DBS)
Number of subjects: 0
Study 29326298 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking duration
Number of subjects: 10187
Study 29326298 — intervention group
Group type: COMPARATOR
Intervention: Pack-years
Number of subjects: 10187
Study 29326320 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 0
Study 29326651 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-gradient direction DWI (3DWI)
Number of subjects: 117
Study 29326651 — intervention group
Group type: COMPARATOR
Intervention: 20-gradient direction DWI (20DWI)
Number of subjects: 117
Study 29326843 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive approach to red blood cell transfusion
Number of subjects: 4800
Study 29326843 — intervention group
Group type: COMPARATOR
Intervention: Liberal approach to red blood cell transfusion
Number of subjects: 4800
Study 29326917 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily PrEP (one pill taken every day)
Number of subjects: 315
Study 29326917 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-driven PrEP (pills taken only around specific risk events)
Number of subjects: 315
Study 29326917 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic PrEP (daily dosing during periods of increased risk)
Number of subjects: 315
Study 29326917 — intervention group
Group type: COMPARATOR
Intervention: Daily PrEP
Number of subjects: 315
Study 29327075 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg orally twice a day, oxaliplatin 85 mg/m2
Number of subjects: 35
Study 29327182 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ferrous fumarate in tablet form (195 mg of elemental iron)
Number of subjects: 24
Study 29327182 — intervention group
Group type: EXPERIMENTAL
Intervention: 1390 mg ferrous gluconate as a solution (160 mg of elemental iron)
Number of subjects: 24
Study 29327948 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor-ivacaftor
Number of subjects: 53
Study 29329141 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectralis optical coherence tomography (Heidelberg Engineering)
Number of subjects: 32
Study 29329555 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (three supervised, high-intensity interval training sessions/week during NACRT and ≥150 min/week of unsupervised, moderate-to-vigorous-intensity continuous exercise training after NACRT)
Number of subjects: 60
Study 29329555 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no increase in exercise from baseline)
Number of subjects: 60
Study 29329568 — intervention group
Group type: EXPERIMENTAL
Intervention: Yttrium-90 (Y90) radioembolization
Number of subjects: 30
Study 29329602 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept plus MTX (all csDMARDs pooled)
Number of subjects: 3113
Study 29329602 — intervention group
Group type: COMPARATOR
Intervention: Abatacept plus non-MTX csDMARDs
Number of subjects: 3113
Study 29329602 — intervention group
Group type: COMPARATOR
Intervention: Abatacept plus MTX
Number of subjects: 3113
Study 29329602 — intervention group
Group type: COMPARATOR
Intervention: Abatacept plus one non-MTX csDMARD
Number of subjects: 3113
Study 29329991 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced EUS (CE-EUS)
Number of subjects: 28
Study 29329992 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS elastography (strain ratio) - parenchymal strain ratio (pSR)
Number of subjects: 100
Study 29329992 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS elastography (strain ratio) - wall strain ratio (wSR)
Number of subjects: 100
Study 29329992 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS elastography with pSR cut-off at 9.10
Number of subjects: 100
Study 29329992 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS elastography with wSR cut-off at 16.2
Number of subjects: 100
Study 29329992 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractal analysis of malignant lesions
Number of subjects: 100
Study 29329992 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractal analysis across all 3 channels (red, green, blue)
Number of subjects: 100
Study 29330398 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Number of subjects: 0
Study 29330625 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy (AET)
Number of subjects: 116
Study 29330625 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial necessity-concern beliefs about AET
Number of subjects: 116
Study 29330625 — intervention group
Group type: EXPERIMENTAL
Intervention: Expected side-effect severity
Number of subjects: 116
Study 29330639 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (SA)
Number of subjects: 19
Study 29330782 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan 5 mg single oral administration
Number of subjects: 2
Study 29330782 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan administered with itraconazole
Number of subjects: 2
Study 29330858 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleus Hybrid L24 cochlear implant
Number of subjects: 32
Study 29330858 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleus Hybrid L24 cochlear implant with electric-acoustic stimulation
Number of subjects: 32
Study 29331245 — intervention group
Group type: EXPERIMENTAL
Intervention: Outsmart HPV intervention (population-targeted, individually-tailored content)
Number of subjects: 150
Study 29331245 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard HPV vaccination information)
Number of subjects: 150
Study 29331936 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized foot orthoses (CFO)
Number of subjects: 20
Study 29331936 — intervention group
Group type: COMPARATOR
Intervention: No CFO utilization
Number of subjects: 20
Study 29331969 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic treatment initiated at diagnosis
Number of subjects: 3482
Study 29331969 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-recommended therapy
Number of subjects: 3482
Study 29331971 — intervention group
Group type: EXPERIMENTAL
Intervention: Lantern mobile cognitive-behavioural programme
Number of subjects: 0
Study 29331971 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (control)
Number of subjects: 0
Study 29331988 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV positive individuals (PLWHIV)
Number of subjects: 1098
Study 29331988 — intervention group
Group type: COMPARATOR
Intervention: Uninfected controls
Number of subjects: 1098
Study 29332626 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative symptoms of depression
Number of subjects: 1125
Study 29332626 — intervention group
Group type: EXPERIMENTAL
Intervention: One-year post-surgery symptoms of depression
Number of subjects: 1125
Study 29332633 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological factors (anxiety and depression)
Number of subjects: 55
Study 29332633 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-min walk distance (6MWD)
Number of subjects: 55
Study 29332633 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta SPO
Number of subjects: 55
Study 29333159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous microwave ablation (MWA)
Number of subjects: 75
Study 29333159 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 75
Study 29333165 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardial injections of autologous VEGF-A
Number of subjects: 0
Study 29333165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29333880 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 764
Study 29333880 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Number of subjects: 764
Study 29334265 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated hypertension
Number of subjects: 320
Study 29334265 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset hypertension during follow-up
Number of subjects: 320
Study 29334265 — intervention group
Group type: COMPARATOR
Intervention: Uncontrolled treated hypertension
Number of subjects: 320
Study 29334491 — intervention group
Group type: EXPERIMENTAL
Intervention: AZL-M/CTD 20/12.5 mg once daily titrated to 40/25 mg if needed
Number of subjects: 1085